Microba Launches Next Generation Healthcare Testing
28.2.2023 12:44:00 EET | Business Wire | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005713/en/
MetaXplore™ GI Plus can help you explore the impact your patients’ gut microbiome may be having on their health. MetaXplore™ GI Plus translates diagnostic gastrointestinal markers and targeted pathogen, protist and parasite panels1 alongside metagenomic-driven gut microbiome insights2 for over 28,000* microbial species and their function. (Photo: Business Wire)
Microba’s Chief Executive Officer, Dr Luke Reid said, “The new MetaXplore™ test range delivers an important advancement in how microbiome test information can be applied in a healthcare setting. We continue to make progress at the forefront of this field to advance the application of microbiome testing in a healthcare setting towards a future where it can be routine in health and disease management, much like a blood test is today.”
The new MetaXplore™ range provides diagnostic gastrointestinal health testing together with metagenomic-driven gut microbiome analysis to deliver comprehensive gastrointestinal testing solutions for Healthcare Professionals. The MetaXplore™ test range has been developed together with healthcare professionals and brought to market under a new brand called Co-Biome™.
The range consists of 3 products: MetaXplore™, MetaXplore™ GI and MetaXplore™ GI Plus. Key features include:
- Easy to interpret report format designed specifically for healthcare professionals to support efficient patient consultation
- Scientifically graded clinical insights using National Health and Medical Research Council guidelines
- Diagnostic and investigative gastrointestinal health markers (faecal calprotectin, faecal occult blood, lactoferrin, pancreatic elastase, secretory IgA, Zonulin, Fecal pH)
- Diagnostic pathogen and parasite detection (E.coli pathotypes, C.difficile pathotypes, Campylobacter spp., Yersinia enterocolitica, Vibrio spp., Aeromonas spp., Salmonella spp., Giardia lamblia, Entamoeba histolytica, Cryptosporidium spp., Dientamoeba fragilis, Cyclospora cayetanensis.)
- Complete microbiome profiling (Microbial diversity, richness and profiling of over 28,000+ microbial species including bacteria, fungi, parasite and archaea detection, together with parasite detection of Blastocystis subtypes 1-9 and other eukaryotes)
- Microbiome production and consumption of metabolites (Butyrate, acetate, propionate, 3-indolepropionic acid (IPA), hexa-acylated, lipopolysaccharides (hexa-LPS), trimethylamine (TMA), hydrogen sulphide, branched-chain amino acids (BCAA), B.fragilis toxin, methane, beta-glucuronidase, Mucin, oxalate)
A core component of Microba’s strategy is to leverage the Company’s world-leading technology and capability to advance the clinical application of microbiome testing to become embedded as a routine part of health and disease management. The MetaXplore™ test range through Co-Biome™ represents an important step forward in that strategy by breaking new ground in the application of microbiome testing in healthcare.
Microba’s Chief Scientific Officer, Assoc Prof. Lutz Krause said, “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting. This test range is expected to significantly expand the total addressable market for Microba’s testing products.”
The test range through Co-Biome™ can be accessed in Australia through a healthcare professional, and following the launch, it is expected to then be rolled out through Microba’s growing international distribution partner network.
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005713/en/
Contact information
Simon Hinsley simon@nwrcommunications.com.au
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice and NXP Deliver Flexible, Secure Computing Solution for the Industrial Edge10.11.2026 23:00:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced the Lattice NXP PCIe® Companion solution, jointly enabled and promoted with NXP® Semiconductors. Pairing NXP’s i.MX 95 applications processor with Lattice Nexus™-based FPGAs over PCIe, the solution addresses the real-time connectivity, deterministic I/O, and security challenges in industrial automation, robotics, and intelligent edge applications. The joint solution is available in Lattice CertusPro™-NX or Lattice Certus™-NX configurations as companion chips to NXP i.MX 95 SoC compute processors, deepening a long-standing collaboration between Lattice and NXP spanning industrial, data center, and networking applications. The Lattice FPGA adds low latency, deterministic I/O alongside the NXP applications processor, delivering combined capabilities across real-time processing, AI, and custom I/O to help customers modernize aging designs for new interface standards. It supports e
FDA Approves PIMJETMI ® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor10.11.2026 20:14:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. “People living with TGCT have long faced difficult treatment decisions as they navigate a disease that can significantly affect their daily lives including their mobility,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board for the Healthcare business of Merck. “Translating scientific innovation into clinically meaningful advances for people living with rare tumors is a strategic imperative for our company, as we continue our commitment to addressing significant unmet needs. With the approval of PIMJETMI in the U.S., we strengthen our leadership position and growing
Smartsheet Integrates With Claude Sheets, Making It Easy to Start Projects in Claude and Launch Workflows Across Teams with Smartsheet10.11.2026 19:57:00 EET | Press release
Smartsheet, the AI-powered enterprise work management platform, today announced a new integration with Claude Sheets, the new spreadsheet artifact in Claude from Anthropic, now in beta. With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. There they can put it to work with their team, connected to the plans, projects, people and systems their organization already runs on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110763156/en/ With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. More and more work now begins in a conversation with Claude, and the Smartsheet MCP connector for Claude puts the entire power of the Smartsheet platform into play for users. Now with Claude Sheets, a person can think through a launch plan, a project tracker or a budget, and shape with the
InterSystems Joins Google Cloud as Launch Partner for Gemini for Healthcare10.11.2026 19:00:00 EET | Press release
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced that it will serve as a launch partner for Google Cloud’s Gemini for healthcare. Through the collaboration, Gemini for healthcare will connect to the InterSystems IRIS FHIR Model Context Protocol (MCP) server, enabling healthcare organizations to give AI assistants and agents governed access to FHIR data. The integration will bring together Google Cloud’s Gemini capabilities and the standards-based data access provided by InterSystems IRIS FHIR MCP. InterSystems FHIR MCP serves the open Model Context Protocol directly from a FHIR endpoint, allowing MCP-enabled clients to discover and use FHIR tools for searching, reading, creating, updating, and managing healthcare data. “Healthcare organizations are looking for practical ways to apply AI to their data without compromising security, governance, or interoperability,” said Don Woodlock, president of InterSystems. “By
Coherent Solutions Launches AKTIV, a Dedicated Fitness and Wellness Technology Business Unit10.11.2026 17:34:00 EET | Press release
Coherent Solutions officially launches AKTIV, a dedicated business unit focused exclusively on fitness and wellness technology. AKTIV brings together over 15 years of fitness industry experience, dedicated leadership, and global engineering capabilities to help fitness and wellness operators and equipment manufacturers compete through technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110242555/en/ Coherent Solutions officially launches AKTIV “We know the fitness and wellness industry and the challenges operators and manufacturers face. With AKTIV, we spend less time defining what needs to be built and more time delivering solutions that improve operations, member experiences, and business performance,” said Vadim Bartlov, Managing Director of AKTIV. AKTIV builds on Coherent Solutions' established work with leading fitness companies, including Life Time, Planet Fitness, Anytime Fitness, Orangetheory, and BowFlex,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom